Clinical Trial Update: A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of risperidone for preventing relapse in children and adolescents with conduct and other disruptive behavior di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Conduct Disorder
• Disruptive Behavior Disorders
• Oppositional Defiant Disorder

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Attention Deficit and Disruptive Behavior Disorders | Phase 3 | Status: COMPLETED